InnoCare Pharma Limited is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments, primarily targeting cancer and autoimmune disorders. A key product in their portfolio is Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. This therapy targets various relapsed or refractory blood cancers, including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, diffuse large B-cell lymphoma (MCD subtype), central nervous system lymphoma, and is also being explored in combination with MIL-62. Furthermore, Orelabrutinib is under investigation for a range of autoimmune conditions such as systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company's broader pipeline features several investigational candidates in various clinical trial stages. For example, ICP-192, a pan-FGFR inhibitor, is currently in Phase I/II trials for solid tumors like cholangiocarcinoma and head and neck cancer. Compounds in Phase I clinical trials include ICP-723, a pan-TRK inhibitor addressing cancers with neurotrophic tyrosine receptor kinase fusions; ICP-332, a novel tyrosine kinase 2 (TYK2) inhibitor for autoimmune diseases; and ICP-B02, a bispecific antibody targeting lymphoma. Further preclinical and early-stage assets encompass ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver, renal cell, colorectal, and other solid tumors; ICP-488 for autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for various cancers; and ICP-248 and ICP-490, both focusing on hematological conditions, with ICP-490 also extending to autoimmune diseases. Additionally, InnoCare offers Tafasitamab (marketed as ICP-B04), indicated for the treatment of diffuse large B-cell lymphoma and other hematological malignancies. Established in 2015, InnoCare Pharma Limited maintains its headquarters in Beijing, China.
—
InnoCare Pharma Limited is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments, primarily targeting cancer and autoimmune disorders. A key product in their portfolio is Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. This therapy targets various relapsed or refractory blood cancers, including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, diffuse large B-cell lymphoma (MCD subtype), central nervous system lymphoma, and is also being explored in combination with MIL-62. Furthermore, Orelabrutinib is under investigation for a range of autoimmune conditions such as systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company's broader pipeline features several investigational candidates in various clinical trial stages. For example, ICP-192, a pan-FGFR inhibitor, is currently in Phase I/II trials for solid tumors like cholangiocarcinoma and head and neck cancer. Compounds in Phase I clinical trials include ICP-723, a pan-TRK inhibitor addressing cancers with neurotrophic tyrosine receptor kinase fusions; ICP-332, a novel tyrosine kinase 2 (TYK2) inhibitor for autoimmune diseases; and ICP-B02, a bispecific antibody targeting lymphoma. Further preclinical and early-stage assets encompass ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver, renal cell, colorectal, and other solid tumors; ICP-488 for autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for various cancers; and ICP-248 and ICP-490, both focusing on hematological conditions, with ICP-490 also extending to autoimmune diseases. Additionally, InnoCare offers Tafasitamab (marketed as ICP-B04), indicated for the treatment of diffuse large B-cell lymphoma and other hematological malignancies. Established in 2015, InnoCare Pharma Limited maintains its headquarters in Beijing, China.
—
Daily adjusted close
InnoCare Pharma Limited is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments, primarily targeting cancer and autoimmune disorders. A key product in their portfolio is Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. This therapy targets various relapsed or refractory blood cancers, including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, diffuse large B-cell lymphoma (MCD subtype), central nervous system lymphoma, and is also being explored in combination with MIL-62. Furthermore, Orelabrutinib is under investigation for a range of autoimmune conditions such as systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company's broader pipeline features several investigational candidates in various clinical trial stages. For example, ICP-192, a pan-FGFR inhibitor, is currently in Phase I/II trials for solid tumors like cholangiocarcinoma and head and neck cancer. Compounds in Phase I clinical trials include ICP-723, a pan-TRK inhibitor addressing cancers with neurotrophic tyrosine receptor kinase fusions; ICP-332, a novel tyrosine kinase 2 (TYK2) inhibitor for autoimmune diseases; and ICP-B02, a bispecific antibody targeting lymphoma. Further preclinical and early-stage assets encompass ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver, renal cell, colorectal, and other solid tumors; ICP-488 for autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for various cancers; and ICP-248 and ICP-490, both focusing on hematological conditions, with ICP-490 also extending to autoimmune diseases. Additionally, InnoCare offers Tafasitamab (marketed as ICP-B04), indicated for the treatment of diffuse large B-cell lymphoma and other hematological malignancies. Established in 2015, InnoCare Pharma Limited maintains its headquarters in Beijing, China.